CLDX Celldex Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLDX

Price (delayed)

$44.56

Market cap

$2.94B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.86

Enterprise value

$2.82B

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which ...

Highlights
Celldex Therapeutics's equity has soared by 177% YoY and by 95% from the previous quarter
CLDX's quick ratio has surged by 130% since the previous quarter and by 71% year-on-year
Celldex Therapeutics's revenue has soared by 93% YoY but it has decreased by 12% from the previous quarter
The company's gross profit has surged by 93% YoY but it fell by 12% QoQ
Celldex Therapeutics's net income has decreased by 22% YoY and by 2.4% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.celldex.com
Peers: AGEN EBS NWBO PFE

Key stats

What are the main financial stats of CLDX
Market
Shares outstanding
65.91M
Market cap
$2.94B
Enterprise value
$2.82B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.97
Price to sales (P/S)
432.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
465.09
Earnings
Revenue
$6.07M
EBIT
-$144.88M
EBITDA
-$141.82M
Free cash flow
-$120.94M
Per share
EPS
-$2.86
Free cash flow per share
-$2.05
Book value per share
$15
Revenue per share
$0.1
TBVPS
$14.3
Balance sheet
Total assets
$868.85M
Total liabilities
$30.23M
Debt
$2.11M
Equity
$838.61M
Working capital
$809.03M
Liquidity
Debt to equity
0
Current ratio
31.77
Quick ratio
31.44
Net debt/EBITDA
0.8
Margins
EBITDA margin
-2,335.6%
Gross margin
100%
Net margin
-2,386%
Operating margin
-2,679.2%
Efficiency
Return on assets
-30.3%
Return on equity
-32.3%
Return on invested capital
-38.2%
Return on capital employed
-17.2%
Return on sales
-2,386%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLDX stock price

How has the Celldex Therapeutics stock price performed over time
Intraday
1.6%
1 week
21.22%
1 month
23.4%
1 year
24.26%
YTD
12.36%
QTD
20.4%

Financial performance

How have Celldex Therapeutics's revenue and profit performed over time
Revenue
$6.07M
Gross profit
$6.07M
Operating income
-$162.68M
Net income
-$144.88M
Gross margin
100%
Net margin
-2,386%
Celldex Therapeutics's revenue has soared by 93% YoY but it has decreased by 12% from the previous quarter
The company's gross profit has surged by 93% YoY but it fell by 12% QoQ
The net margin has increased by 37% YoY but it has decreased by 16% QoQ
CLDX's operating margin is up by 35% year-on-year but it is down by 19% since the previous quarter

Growth

What is Celldex Therapeutics's growth rate over time

Valuation

What is Celldex Therapeutics stock price valuation
P/E
N/A
P/B
2.97
P/S
432.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
465.09
CLDX's EPS is down by 13% YoY but it is up by 2.1% from the previous quarter
Celldex Therapeutics's equity has soared by 177% YoY and by 95% from the previous quarter
The P/B is 37% lower than the last 4 quarters average of 4.6 and 21% lower than the 5-year quarterly average of 3.7
Celldex Therapeutics's revenue has soared by 93% YoY but it has decreased by 12% from the previous quarter
CLDX's price to sales (P/S) is 15% higher than its last 4 quarters average of 369.2 and 11% higher than its 5-year quarterly average of 383.8

Efficiency

How efficient is Celldex Therapeutics business performance
CLDX's ROS is up by 37% YoY but it is down by 16% from the previous quarter
Celldex Therapeutics's ROIC has increased by 29% from the previous quarter and by 8% YoY
The ROE has grown by 28% from the previous quarter and by 9% YoY
The ROA is up by 27% QoQ and by 7% YoY

Dividends

What is CLDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLDX.

Financial health

How did Celldex Therapeutics financials performed over time
Celldex Therapeutics's total assets has soared by 168% YoY and by 87% from the previous quarter
CLDX's quick ratio has surged by 130% since the previous quarter and by 71% year-on-year
The debt is 100% lower than the equity
Celldex Therapeutics's equity has soared by 177% YoY and by 95% from the previous quarter
CLDX's debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.